Intelligence · Clinical Pipeline
Rare disease · Phase I
Rare disease programs at Phase I — ClinicalTrials.gov pipeline intelligence.
- Programs
- 4
Quick answer
Rare disease Phase I programs: NovaPharmaNews indexes 4 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
-
A study to investigate the effect of capivasertib on the pharmacokinetics of oral dextromethorphan (CYP2D6) in healthy participants
AstraZeneca AB
Healthy participants
1 trial -
DEXTROMETHORPHANE ELERTE 1,5 mg/ml, sirop, AZD3470, AZD3470, Midazolam-ratiopharm® 2 mg/ml orale Lösung
AstraZeneca AB
Advanced/metastatic solid tumors that are MTAP deficient.
1 trial -
Dextromethorphan HBr
Galera Therapeutics
Healthy
1 trial -
STRATIFY; Near-infrared fluorescence molecular imaging of adalimumab-800CW to elucidate the drug distribution throughout inflamed tissue in inflammatory bowel disease and rheumatoid arthritis
Disc Medicine
Crohn's disease, Spondyloarthritis, Rheumatoid arthritis, Ulcerative colitis
1 trial
Frequently asked questions
How many rare disease Phase I programs exist?
4 programs match both the therapeutic area and stage filters in our published index.
Data attribution: Data sources · All pipeline programs